245 related articles for article (PubMed ID: 30529500)
1. Generation of two high affinity anti-mouse FcRn antibodies: Inhibition of IgG recycling in wild type mice and effect in a mouse model of immune thrombocytopenia.
Smith B; Christodoulou L; Clargo A; Eddleston A; Greenslade K; Lightwood D; Shock A; Tyson K; Brennan FR
Int Immunopharmacol; 2019 Jan; 66():362-365. PubMed ID: 30529500
[TBL] [Abstract][Full Text] [Related]
2. The neonatal Fc receptor (FcRn) is not required for IVIg or anti-CD44 monoclonal antibody-mediated amelioration of murine immune thrombocytopenia.
Crow AR; Suppa SJ; Chen X; Mott PJ; Lazarus AH
Blood; 2011 Dec; 118(24):6403-6. PubMed ID: 22001393
[TBL] [Abstract][Full Text] [Related]
3. Neonatal Fc receptor in human immunity: Function and role in therapeutic intervention.
Patel DD; Bussel JB
J Allergy Clin Immunol; 2020 Sep; 146(3):467-478. PubMed ID: 32896307
[TBL] [Abstract][Full Text] [Related]
4. Animal model of fetal and neonatal immune thrombocytopenia: role of neonatal Fc receptor in the pathogenesis and therapy.
Chen P; Li C; Lang S; Zhu G; Reheman A; Spring CM; Freedman J; Ni H
Blood; 2010 Nov; 116(18):3660-8. PubMed ID: 20647570
[TBL] [Abstract][Full Text] [Related]
5. Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration.
Smith B; Kiessling A; Lledo-Garcia R; Dixon KL; Christodoulou L; Catley MC; Atherfold P; D'Hooghe LE; Finney H; Greenslade K; Hailu H; Kevorkian L; Lightwood D; Meier C; Munro R; Qureshi O; Sarkar K; Shaw SP; Tewari R; Turner A; Tyson K; West S; Shaw S; Brennan FR
MAbs; 2018 Oct; 10(7):1111-1130. PubMed ID: 30130439
[TBL] [Abstract][Full Text] [Related]
6. Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases.
Li N; Zhao M; Hilario-Vargas J; Prisayanh P; Warren S; Diaz LA; Roopenian DC; Liu Z
J Clin Invest; 2005 Dec; 115(12):3440-50. PubMed ID: 16284651
[TBL] [Abstract][Full Text] [Related]
7. Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering.
Wang Y; Tian Z; Thirumalai D; Zhang X
J Drug Target; 2014 May; 22(4):269-78. PubMed ID: 24404896
[TBL] [Abstract][Full Text] [Related]
8. Intravenous immunoglobulin mediates an increase in anti-platelet antibody clearance via the FcRn receptor.
Hansen RJ; Balthasar JP
Thromb Haemost; 2002 Dec; 88(6):898-9. PubMed ID: 12529736
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic/pharmacodynamic modeling of the effects of intravenous immunoglobulin on the disposition of antiplatelet antibodies in a rat model of immune thrombocytopenia.
Hansen RJ; Balthasar JP
J Pharm Sci; 2003 Jun; 92(6):1206-15. PubMed ID: 12761810
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia.
Teeling JL; Jansen-Hendriks T; Kuijpers TW; de Haas M; van de Winkel JG; Hack CE; Bleeker WK
Blood; 2001 Aug; 98(4):1095-9. PubMed ID: 11493456
[TBL] [Abstract][Full Text] [Related]
11. Measuring the Impact of Targeting FcRn-Mediated IgG Recycling on Donor-Specific Alloantibodies in a Sensitized NHP Model.
Manook M; Flores WJ; Schmitz R; Fitch Z; Yoon J; Bae Y; Shaw B; Kirk A; Harnois M; Permar S; Farris AB; Magnani DM; Kwun J; Knechtle S
Front Immunol; 2021; 12():660900. PubMed ID: 34149698
[TBL] [Abstract][Full Text] [Related]
12. Effects of intravenous immunoglobulin on platelet count and antiplatelet antibody disposition in a rat model of immune thrombocytopenia.
Hansen RJ; Balthasar JP
Blood; 2002 Sep; 100(6):2087-93. PubMed ID: 12200371
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal IgG can ameliorate immune thrombocytopenia in a murine model of ITP: an alternative to IVIG.
Song S; Crow AR; Freedman J; Lazarus AH
Blood; 2003 May; 101(9):3708-13. PubMed ID: 12506021
[TBL] [Abstract][Full Text] [Related]
14. FcRn augments induction of tissue factor activity by IgG-containing immune complexes.
Cines DB; Zaitsev S; Rauova L; Rux AH; Stepanova V; Krishnaswamy S; Sarkar A; Kowalska MA; Zhao G; Mast AE; Blumberg LJ; McCrae KR; Poncz M; Hubbard JJ; Pyzik M; Blumberg RS
Blood; 2020 Jun; 135(23):2085-2093. PubMed ID: 32187355
[TBL] [Abstract][Full Text] [Related]
15. The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity.
Abdiche YN; Yeung YA; Chaparro-Riggers J; Barman I; Strop P; Chin SM; Pham A; Bolton G; McDonough D; Lindquist K; Pons J; Rajpal A
MAbs; 2015; 7(2):331-43. PubMed ID: 25658443
[TBL] [Abstract][Full Text] [Related]
16. The maternal immune response to fetal platelet GPIbα causes frequent miscarriage in mice that can be prevented by intravenous IgG and anti-FcRn therapies.
Li C; Piran S; Chen P; Lang S; Zarpellon A; Jin JW; Zhu G; Reheman A; van der Wal DE; Simpson EK; Ni R; Gross PL; Ware J; Ruggeri ZM; Freedman J; Ni H
J Clin Invest; 2011 Nov; 121(11):4537-47. PubMed ID: 22019589
[TBL] [Abstract][Full Text] [Related]
17. Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia.
Newland AC; Sánchez-González B; Rejtő L; Egyed M; Romanyuk N; Godar M; Verschueren K; Gandini D; Ulrichts P; Beauchamp J; Dreier T; Ward ES; Michel M; Liebman HA; de Haard H; Leupin N; Kuter DJ
Am J Hematol; 2020 Feb; 95(2):178-187. PubMed ID: 31821591
[TBL] [Abstract][Full Text] [Related]
18. Antineonatal Fc Receptor Antibody Treatment Ameliorates MOG-IgG-Associated Experimental Autoimmune Encephalomyelitis.
Remlinger J; Madarasz A; Guse K; Hoepner R; Bagnoud M; Meli I; Feil M; Abegg M; Linington C; Shock A; Boroojerdi B; Kiessling P; Smith B; Enzmann V; Chan A; Salmen A
Neurol Neuroimmunol Neuroinflamm; 2022 Mar; 9(2):. PubMed ID: 35027475
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic/pharmacodynamic modeling of IVIG effects in a murine model of immune thrombocytopenia.
Deng R; Balthasar JP
J Pharm Sci; 2007 Jun; 96(6):1625-37. PubMed ID: 17238194
[TBL] [Abstract][Full Text] [Related]
20. Application of Physiologically Based Pharmacokinetic Modeling to Predict the Effects of FcRn Inhibitors in Mice, Rats, and Monkeys.
Li T; Balthasar JP
J Pharm Sci; 2019 Jan; 108(1):701-713. PubMed ID: 30423340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
